← Back to Clinical Trials
Recruiting NCT05229341

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

Trial Parameters

Condition Thyroid Gland Carcinoma
Sponsor City of Hope Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 1,450
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2021-10-22
Completion 2026-10-22
Interventions
Diagnostic ProcedureElectronic Health Record ReviewNeedle Biopsy

Brief Summary

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

Eligibility Criteria

Inclusion Criteria: * Patients without impaired decision-making capacity and who are undergoing needle biopsies for thyroid nodule diagnosis * Over the age of 18 * Any gender, race and ethnicity * Patients must provide informed consent prior to use of their tissues and clinical data Exclusion Criteria: * Children are excluded from the study, since the biology of children thyroid nodules is different from adults

Related Trials